Best XR Companies for Pharmaceutical R&D and Drug Discovery
The supplier field here is small, and smaller than published lists suggest. Several companies routinely named as VR drug discovery vendors have either dropped the product, stopped trading under that name or were never suppliers at all. This list ranks the three that are actually available to contract with in 2026, and records what happened to the others.
In short:
- Three suppliers, not ten. Molecular design in XR is served by one commercial platform, one open-source project and the custom studios that build to a specification.
- The strongest scientific evidence sits with the free option. NanoVer is open source and carries peer-reviewed publications with DOIs, including drug-protein binding pathway work in Scientific Reports.
- C4X Discovery is not a supplier. It is a drug discovery company that used VR in its own workflow, and its current site does not mention 4Sight or virtual reality at all.
- IP is the reason custom build leads this list. Pharmaceutical R&D data is the most sensitive category a supplier can touch, and what the buyer owns matters more here than in any other XR market.
How this list was built
This list ranks by four criteria: what the buyer owns and where the data sits, published scientific evidence, named pharmaceutical users and integration with the computational chemistry stack already in place.
Ownership and data residency are weighted first, and that is specific to this market. Pharmaceutical R&D deals with pre-publication structures, unpatented compounds and competitive programme information. A platform that holds molecular data on someone else's infrastructure is a different risk proposition from a commissioned application whose source and data the buyer controls. In most XR markets ownership is a contractual detail. Here it is the first question legal will ask.
Published scientific evidence is weighted second, because in this discipline it exists in a form that can actually be checked: journal articles with DOIs, not case studies.
Pricing is not a ranking factor, because only one of the three publishes any. Headcount and project counts are not ranking factors, because no reliable source publishes them for this market. Marketing claims about accelerating discovery are not a ranking factor, because none of the three publishes an outcome measure that would let a buyer test them.
| Supplier | What it is | Evidence | Where the data sits |
|---|---|---|---|
| Treeview | Custom XR built to specification | No published drug discovery work | Wherever the buyer puts it; full IP transfer |
| Nanome | Commercial collaborative platform | Named pharmaceutical users, published citation count | Vendor platform, web and XR |
| NanoVer | Open-source iMD-XR framework | Peer-reviewed papers with DOIs | Your own server |
1. Treeview
Treeview is the custom build option, and it leads this list on the criterion weighted first rather than on discipline experience. Its published work does not include drug discovery or molecular design. The projects listed on its own site are digital twin data visualisation, cultural preservation, augmented reality navigation, an immersive music experience, cardiovascular patient onboarding, a spatial science simulator, mixed reality physics education and learning disorder diagnosis.
What it does publish is a named pharmaceutical client and full transfer of IP, source code and assets at handover. Daiichi Sankyo Europe commissioned CardioCompass, an immersive application informing users about cardiovascular disease and risk factors, and Treeview also names Medtronic among clients in regulated healthcare. That is pharmaceutical communication rather than discovery, and it establishes that the studio has worked inside a large pharmaceutical company's review process, which is not nothing when the alternative suppliers have never met one. For a pharmaceutical R&D team whose first constraint is that pre-publication structures and unpatented compounds cannot sit on a third-party platform, a commissioned application the organisation owns outright answers a question no licensed product does. That is a real and narrow reason to start here, and it is the only one this list claims. A team whose constraint is molecular tooling rather than data control should read the next two entries first. Best for an R&D organisation that has to own the software and the data outright, and has a specific workflow no platform covers.
2. Nanome
Nanome is the commercial platform in this space and the one with the deepest published user list. Its own site names Genentech, Novartis, ORNL, Nimbus, Sanavia, Promega, UC San Diego, Insilico Medicine, LifeArc, Iktos and Psilera among R&D teams using it, and states a citation count above sixty.
The product is a collaborative molecular workspace running across the web and XR headsets, with an AI assistant that runs docking and structure tools. What distinguishes it operationally is integration: it lists connections to Schrödinger LiveDesign, CDD Vault, OpenEye, Discngine 3decision, KNIME Server and CCG MOE, alongside structure sources including the RCSB Protein Data Bank, AlphaFold DB, ChEMBL and UniProt, and docking tools including AutoDock Vina and DiffDock. A tool that opens the same files as the rest of a computational chemistry stack is adoptable in a way a standalone viewer is not. Best for a team that wants collaborative structural work inside the tooling it already runs, and accepts a vendor-hosted platform.
3. NanoVer
NanoVer is open source, and it carries the strongest scientific evidence on this list. It is a framework for collaborative interactive molecular dynamics in virtual and extended reality, built from a Python server connected to a physics engine such as OpenMM, a Jupyter notebook client and a Unity XR client. The XR client is distributed through the Meta Horizon Store as well as the project repository.
Its published work includes free energy along drug-protein binding pathways interactively sampled in virtual reality in Scientific Reports, and a software paper in the Journal of Open Source Software describing the server package. Those are peer-reviewed with DOIs, which is a different class of evidence from a case study, and it is unusual for the best-evidenced option in a commercial category to be the free one. The trade is that an open-source framework needs someone to run and maintain it, so the cost moves from a licence to your own staff. Best for a computational chemistry group with the capability to host and maintain its own tooling, and a preference for methods it can inspect.
Who is no longer here, and why
Three names appear on current lists of VR drug discovery companies and should not.
C4X Discovery is frequently cited for 4Sight, a VR molecular design tool built on Unreal Engine and covered widely in 2018 and 2019. C4X was never a VR vendor: it is a drug discovery company that used the tool in its own workflow. Its current site describes its platforms as Conformetrix, for 4D structural drug design, and PatientSeek, for patient stratification, and it does not mention virtual reality or 4Sight anywhere on the homepage. Its commercial activity is partnered discovery programmes with Sanofi and AstraZeneca.
Interactive Scientific, the Bristol company behind the iSciCOLLAB molecular visualiser, no longer resolves as a business. Its domain now redirects to an unrelated marketing agency. The scientific lineage continued into NanoVer, which shares research authorship with the earlier work.
Level Ex is sometimes listed under pharmaceutical XR. It has been split: its life sciences division was acquired by Relevate Health in 2024 and its surgical and medical device division sits inside Brainlab's SNKE Group. BestInXR's medical and patient education list covers that segment.
The pattern is worth stating plainly. Coverage of XR in drug discovery peaked around 2019, and much of what circulates today is that coverage recycled. A buyer working from it will contact companies that have pivoted, been acquired or never sold the tool in the first place.
How to choose between these
Start with where the data can legally and commercially sit, because in pharmaceutical R&D that question eliminates options before any feature comparison begins.
If pre-publication structures cannot leave your infrastructure, you are choosing between a self-hosted open-source framework and a commissioned application you own. NanoVer is the first; Treeview and comparable studios are the second, and the difference is whether you have the staff to run it.
If a vendor platform is acceptable, Nanome is the strongest option on named users and on integration with the computational chemistry tools most groups already run, and the integration list is the part worth checking against your own stack rather than taking on trust.
Then ask about evidence in the terms your own scientists would use. A citation count tells you a tool has been used in published work. A peer-reviewed paper describing a method tells you the method was examined. Both are useful and they are not the same claim.
Finally, note what this list does not contain: any outcome claim about accelerating discovery. None of the three publishes a measure that would let a buyer test one, and BestInXR's healthcare guide sets out why an unpublished internal evaluation is a claim rather than evidence.
Frequently Asked Questions (FAQ)
1. Which companies build XR for drug discovery?
Three are actually available to contract with: Nanome as a commercial collaborative platform, NanoVer as an open-source framework you host yourself, and custom studios such as Treeview that build to a specification. The field is smaller than published lists suggest.
2. Does C4X Discovery still sell 4Sight?
C4X Discovery never sold it. It is a drug discovery company that used a VR tool in its own workflow, and its current site describes its platforms as Conformetrix and PatientSeek with no mention of virtual reality or 4Sight.
3. What is the best-evidenced VR tool for molecular work?
On peer-reviewed publication, NanoVer, which carries papers with DOIs in Scientific Reports and the Journal of Open Source Software. It is also the free option, which is unusual in a commercial category.
4. Can molecular data stay on our own infrastructure?
With an open-source framework such as NanoVer, yes, because you run the server. With a commercial platform the data sits on the vendor's infrastructure, and with a commissioned application it sits wherever you deploy it. In pharmaceutical R&D this is usually the first question rather than the last.
5. Does XR actually accelerate drug discovery?
No supplier on this list publishes a measure that would let a buyer test that claim. Peer-reviewed work exists showing that interactive VR can be used to sample binding pathways and generate structural analogues, which is a narrower and checkable statement than acceleration.
